XML 58 R48.htm IDEA: XBRL DOCUMENT v3.19.2
Deconsolidation and Distribution of AgeX (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Nov. 28, 2018
Aug. 30, 2018
Jun. 30, 2019
Dec. 31, 2018
Nov. 29, 2018
Gain on sale of shares        
AgeX Therapeutics, Inc. [Member]          
Gain on deconsolidation       $ 78,500  
Gain on sale of shares       $ 39,200  
Parent Company [Member]          
Percentage of ownership before transaction   80.40%      
Percentage of ownership after transaction   40.20%      
Parent Company [Member] | Common Stock [Member]          
Number of shares owned 1,700,000        
Percentage of outstanding common stock     4.60%    
Parent Company [Member] | Prorata Basis [Member]          
Common stock, ratio description one share of AgeX common stock for every 10 shares of BioTime common stock owned.        
Parent Company [Member] | Prorata Basis [Member] | Common Stock [Member]          
Common shares issued 12,700,000        
Dividend-in-kind $ 34,400        
Price per share         $ 2.71
Juvenescence Limited [Member]          
Number of share sold   14,400,000      
Percentage of ownership before transaction   5.60%      
Percentage of ownership after transaction   45.80%